These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18351184)

  • 21. The new label for erythropoiesis stimulating agents: the FDA'S sentence.
    Fishbane S; Jhaveri KD
    Semin Dial; 2012 May; 25(3):263-6. PubMed ID: 22515844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Erythropoesis-stimulating agents: 21 years of clinical experience].
    Kes P
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():1-2. PubMed ID: 20235350
    [No Abstract]   [Full Text] [Related]  

  • 24. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis.
    Molina M; Navarro MJ; de Gracia C; Alvarez G; de Alarcon R; Garcia MA
    Ren Fail; 2008; 30(8):778-83. PubMed ID: 18791951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
    Agarwal AK; Singh AK
    Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA approval of Omontys changes the ESA playing field.
    Neumann ME
    Nephrol News Issues; 2012 May; 26(6):17. PubMed ID: 22690453
    [No Abstract]   [Full Text] [Related]  

  • 29. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving regulatory landscape with erythropoiesis-stimulating agents and impact on managed care.
    Fatodu H
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S74-9. PubMed ID: 20297875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Erythropoesis-stimulating agents: past, present and future].
    Kes P; Basić-Jukić N
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():3-6. PubMed ID: 20235351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaemia in older people with chronic heart failure: The potential cost.
    Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
    Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaemia treatment in chronically dialysed children: a multicentre nationwide observational study.
    Jander A; Wierciński R; Bałasz-Chmielewska I; Miklaszewska M; Zachwieja K; Borzecka H; Zachwieja J; Olszak-Szot I; Kubicki D; Ziółkowska H; Rubik J; Szczepańska M; Runowski D; Fendler W; Tkaczyk M
    Scand J Urol Nephrol; 2012 Oct; 46(5):375-80. PubMed ID: 22587334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of anemia treatment in hemodialysis patients via reinforcement learning.
    Escandell-Montero P; Chermisi M; Martínez-Martínez JM; Gómez-Sanchis J; Barbieri C; Soria-Olivas E; Mari F; Vila-Francés J; Stopper A; Gatti E; Martín-Guerrero JD
    Artif Intell Med; 2014 Sep; 62(1):47-60. PubMed ID: 25091172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaemia of CKD--the CHOIR study revisited.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
    Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
    [No Abstract]   [Full Text] [Related]  

  • 38. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 39. "Out of Sight, Out of Mind": The Failed Renal Allograft as a Cause of ESA Resistance.
    Mehrotra A; Tan JA; Ames SA
    Semin Dial; 2015; 28(5):530-2. PubMed ID: 26096871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
    Schmid H; Schiffl H; Lederer SR
    Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.